RxDoctor Payments Data

Tarun Mehra, MD

Internal Medicine · Baltimore, OHNPI 1659374700

Payments from drug & device makers

$11,943in general payments, 2019–2025

Across 670 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Abbott$844
  • Lilly USA, LLC$640
  • GSK$484
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$11,895100%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,943 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$75,404
Medicare patients
174
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$76,822
JanuviaSitagliptin Phosphate86$70,844
FarxigaDapagliflozin Propanediol79$70,834
JardianceEmpagliflozin40$51,861
OzempicSemaglutide44$50,948
RybelsusSemaglutide41$46,360
Tresiba Flextouch U-200Insulin Degludec21$42,219
XareltoRivaroxaban31$30,820
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$30,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$25,283
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$18,894
SavellaMilnacipran Hcl15$14,479
MyrbetriqMirabegron16$14,191
Albuterol Sulfate HfaAlbuterol Sulfate108$3,981
Atorvastatin Calcium293$3,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$2,874$101,375111 claims
Novo NordiskOzempic, Rybelsus$1,182$97,30885 claims
PfizerEliquis$390$76,82269 claims
MerckJanuvia$197$70,84486 claims
Boehringer IngelheimJardiance$439$51,86140 claims
Johnson & JohnsonXarelto$232$30,82031 claims
GSKTrelegy Ellipta$484$25,28320 claims
AbbVieSavella, Synthroid$1,105$15,60242 claims
Astellas Pharma US IncMyrbetriq$173$14,19116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Baltimore

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →